Answers are grounded in this paper and cite their sources.
BACKGROUND: The initial trials on angiotensin II (AT II) administration indicated a high incidence of thrombocytopenia and thrombosis, as well as a positive correlation between hyperreninemia and response to the medication. CASE SUMMARY: We describe a case of a patient presenting with catecholamine resistant septic shock, thrombocytopenia, deep vein thrombosis, and normal renin concentration who responded immediately to AT II treatment. We observed no worsening of thrombocytopenia and no progression of thrombosis or additional thromboses during treatment. CONCLUSION: Our case underscores the need for individualized assessment of patients for potential therapy with AT II.
No takes yet. Share an insight, caveat, or question.
Brajković et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: